Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
Camidge DR, Moran T, Demedts I, Grosch H, Mileham K, Molina J, Juan-Vidal O, Bepler G, Goldman JW, Park K, Wallin J, Wijayawardana SR, Wang XA, Wacheck V, Smit E. Camidge DR, et al. Among authors: wallin j. Clin Lung Cancer. 2022 Jun;23(4):300-310. doi: 10.1016/j.cllc.2022.03.003. Epub 2022 Mar 17. Clin Lung Cancer. 2022. PMID: 35400584 Clinical Trial.
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
Scagliotti G, Moro-Sibilot D, Kollmeier J, Favaretto A, Cho EK, Grosch H, Kimmich M, Girard N, Tsai CM, Hsia TC, Brighenti M, Schumann C, Wang XA, Wijayawardana SR, Gruver AM, Wallin J, Mansouri K, Wacheck V, Chang GC. Scagliotti G, et al. Among authors: wallin j. J Thorac Oncol. 2020 Jan;15(1):80-90. doi: 10.1016/j.jtho.2019.10.003. Epub 2019 Oct 14. J Thorac Oncol. 2020. PMID: 31622732 Free article. Clinical Trial.
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Kotecki N, Vuagnat P, O'Neil BH, Jalal S, Rottey S, Prenen H, Benhadji KA, Xia M, Szpurka AM, Saha A, Wallin J, Suriyapperuma S, Galvao VR, Geeganage S, Doman TN, Gandhi L, Xu X, Bendell J. Kotecki N, et al. Among authors: wallin j. J Immunother. 2021 Sep 1;44(7):264-275. doi: 10.1097/CJI.0000000000000368. J Immunother. 2021. PMID: 33928928 Clinical Trial.
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
He AR, Cohen RB, Denlinger CS, Sama A, Birnbaum A, Hwang J, Sato T, Lewis N, Mynderse M, Niland M, Giles J, Wallin J, Moser B, Zhang W, Walgren R, Plimack ER. He AR, et al. Among authors: wallin j. Oncologist. 2019 Sep;24(9):e930-e942. doi: 10.1634/theoncologist.2018-0411. Epub 2019 Mar 4. Oncologist. 2019. PMID: 30833489 Free PMC article. Clinical Trial.
Ifosfamide in malignant mesothelioma: a phase II study.
Andersen MK, Krarup-Hansen A, Mårtensson G, Winther-Nielsen H, Thylen A, Damgaard K, Olling S, Wallin J. Andersen MK, et al. Among authors: wallin j. Lung Cancer. 1999 Apr;24(1):39-43. doi: 10.1016/s0169-5002(99)00030-6. Lung Cancer. 1999. PMID: 10403693 Clinical Trial.
375 results